Komori
Share Issuance and Disposal4594BrightPath Biotherapeutics Co.,Ltd.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 21st Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause)

In October 2026, 16,245 of the 21st Series of Stock Acquisition Rights were exercised, and 1,624,500 new shares were issued. As of month-end, 328,755 rights (32,875,500 shares) remained unexercised.

Worth reading
60In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1624500
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

21st Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause)

発行・処分する株式数

Shares issued during the month: 1,624,500 new shares; 0 treasury shares transferred. Stock acquisition rights exercised during the month: 16,245. Unexercised stock acquisition rights as of 5 October 2026: 345,000 (34,500,000 shares). Unexercised stock acquisition rights remaining at month-end: 328,755 (32,875,500 shares)

Intended allottee
PhillipCapital Securities Co., Ltd.
発行済株式総数

Exercise ratio during the month: 4.7% of the total issued. Exercise ratio subject to exercise restrictions: 1.2%

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise price during the month: ¥39–¥47. Details of the adjustment clause and floor: Not disclosed
Number of Stock Acquisition Rights
Total issued: 345,000 rights. Unexercised rights remaining at month-end: 328,755
Offering structure
Underwriter / lead underwriter
PhillipCapital Securities Co., Ltd.
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
5 October 2026: Issuance through a third-party allotment of the 21st Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause); detailed amounts are not stated in this document
Details of issuance or disposal
ItemDetails
Type of issuance or disposal21st Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause)
Number of shares to be issued or disposed ofShares issued during the month: 1,624,500 new shares; 0 treasury shares transferred. Stock acquisition rights exercised during the month: 16,245. Unexercised stock acquisition rights as of 5 October 2026: 345,000 (34,500,000 shares). Unexercised stock acquisition rights remaining at month-end: 328,755 (32,875,500 shares)
Intended allotteePhillipCapital Securities Co., Ltd.
Dilution RateExercise ratio during the month: 4.7% of the total issued. Exercise ratio subject to exercise restrictions: 1.2%
Total number of issued shares138,891,300 shares (as of the end of the month preceding the relevant month) → Not disclosed
Exercise priceExercise price during the month: ¥39–¥47. Details of the adjustment clause and floor: Not disclosed
Number of Stock Acquisition RightsTotal issued: 345,000 rights. Unexercised rights remaining at month-end: 328,755
Underwriter / lead underwriterPhillipCapital Securities Co., Ltd.
Procedures under the Corporate Code of ConductDescribes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing5 October 2026: Issuance through a third-party allotment of the 21st Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause); detailed amounts are not stated in this document
Items this document does not state (18)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status of the 21st Series of Stock Acquisition Rights in October 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 21st Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause) | BrightPath Biotherapeutics Co.,Ltd. (4594) timely disclosure | Komori